Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.
J Immunother Cancer
; 8(2)2020 08.
Article
in En
| MEDLINE
| ID: mdl-32784217
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Interleukin-6
/
Coronavirus Infections
/
Biomarkers, Pharmacological
/
Antibodies, Monoclonal, Humanized
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
J Immunother Cancer
Year:
2020
Document type:
Article